Drug Trial Radar · NCT04433585
A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)
Last checked: Nov 20, 2026Latest source record: Apr 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
291
Actual
Start
Aug 19, 2020
Primary completion
Jan 10, 2023
Study completion Feb 16, 2023
Sponsor
- Lead sponsor
- Nektar TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Eli Lilly and Company
- First posted
- Jun 16, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The reason for this study is to see if the study drug LY3471851 (NKTR-358) is safe and effective in adults with systemic lupus erythematosus (SLE).
Conditions
- Systemic Lupus Erythematosus
Interventions
LY3471851Drug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Achieved a ≥4 Point Reduction in Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) 2000 (2K) Score at Week 24Time frame: Week 24
Locations
112 sites in 19 countries. Site status is shown where the registry gives one.
University of California - San Diego
La Jolla, California
Desert Medical Advances
Palm Desert, California
Stanford University Hospital
Stanford, California
Inland Rheumatology & Osteoporosis Medical Group
Upland, California
University of Colorado School of Medicine
Aurora, Colorado
Clinical Research Center of CT/NY
Danbury, Connecticut
Yale University School of Medicine
New Haven, Connecticut
Stamford Therapeutics Consortium
Stamford, Connecticut
University of Miami School of Medicine
Miami, Florida
New Horizon Research Center
Miami, Florida
NECCR PrimaCare Research
Fall River, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Northwell Health
Great Neck, New York
NYU Langone
New York, New York
MetroHealth Medical Center
Cleveland, Ohio
Paramount Medical Research
Middleburg Heights, Ohio
Oklahoma Medical Research Foundation
Oklahoma City, Oklahoma
Accurate Clinical Management
Baytown, Texas
Metroplex Clinical Research Center
Dallas, Texas
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas
Accurate Clinical Research
Houston, Texas
Fort Bend Clinical Research, LLC
Sugar Land, Texas
University of Washington Medical Center
Seattle, Washington
Hospital J. M. Ramos Mejía
Ciudad Autónoma de Buenos Aire, Argentina
Hospital Córdoba
Córdoba, Argentina
Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan
San Juan, Argentina
DOM- Centro de Reumatologia
CABA, Buenos Aires, Argentina
Centro Privado de Medicina Familiar / Mindout Research
Ciudad Autónoma de Buenos Aire, Buenos Aires, Argentina
APRILLUS Asistencia E Investigacion de Arcis Salud
CABA, Ciudad Autónoma de Buenos Aire, Argentina
Clinica Adventista Belgrano
CABA, Ciudad Autónoma de Buenos Aire, Argentina
Centro de Investigaciones Médicas Tucuman
SAN M. de Tucuman, Tucumán Province, Argentina
Emeritus Research
Camberwell, Victoria, Australia
University of Calgary
Calgary, Alberta, Canada
INREA s.r.o.
Ostrava, Ostrava Město, Czechia
Revmatologicky ustav
Prague, Praha, Hlavní Mešto, Czechia
Universitätsklinikum Köln
Cologne, Germany
Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, Germany
Universitätsklinikum Tübingen
Tübingen, Baden-Wurttemberg, Germany
Universtitätsklinikum Essen AöR
Essen, North Rhine-Westphalia, Germany
Rheumazentrum Ruhrgebiet
Herne, North Rhine-Westphalia, Germany
Showing 40 of 112 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.